INTRODUCTION: Peyronie's disease (PD) is a fibrotic disorder that leads to plaque formation in ∼3-9% of adult men. Connective tissue buildup results in plaque formation, penile curvature and shortening, and in some cases, pain. In the active phase of PD, penile pain is a common symptom, often accompanied by progression in curvature. Treatment options for PD include oral drugs, topical cream, intralesional injections, traction, and shock wave therapy. This article reviews the different treatment options for active-phase PD. AIM: To provide a comprehensive review of the current evidence-based treatments, focusing on active-phase PD. METHODS: A PubMed database search was performed for studies on conservative therapy. We reviewed current clinical practices and trials for the treatment of active-phase PD and assessed their applicability as treatment options. MAIN OUTCOME MEASURE: Define the most recent and effective therapies for the improvement in penile curvature in men presenting with acute PD. RESULTS: A number of trials have resulted in significant benefits in the treatment of PD. Many of the oral therapies studied improved patient outcomes, but the data are insufficient. Similarly, there is no approved topical therapy by guidelines. The best options are intralesional injections of collagenase Clostridium histolyticum (CCh) and interferon-α2b. Shock wave therapy is not recommended for treatment of curvature, but has been shown to improve pain. Traction therapy may have a role in improving PD curve and penile length. CONCLUSION: PD remains a challenge for urologists. Evidence suggests that, for oral therapy, a combination of drugs produces better results. Shock wave therapy is still unproven. Intralesional therapy delivers the best evidence for improvement in the active phase. CCh is the only FDA-approved treatment option available. Penile traction therapy may improve patient outcomes. Brimley SC, Yafi FA, Greenberg J, et al. Review of Management Options for Active-Phase Peyronie's Disease. Sex Med Rev 2019;7:329-337.
INTRODUCTION:Peyronie's disease (PD) is a fibrotic disorder that leads to plaque formation in ∼3-9% of adult men. Connective tissue buildup results in plaque formation, penile curvature and shortening, and in some cases, pain. In the active phase of PD, penile pain is a common symptom, often accompanied by progression in curvature. Treatment options for PD include oral drugs, topical cream, intralesional injections, traction, and shock wave therapy. This article reviews the different treatment options for active-phase PD. AIM: To provide a comprehensive review of the current evidence-based treatments, focusing on active-phase PD. METHODS: A PubMed database search was performed for studies on conservative therapy. We reviewed current clinical practices and trials for the treatment of active-phase PD and assessed their applicability as treatment options. MAIN OUTCOME MEASURE: Define the most recent and effective therapies for the improvement in penile curvature in men presenting with acute PD. RESULTS: A number of trials have resulted in significant benefits in the treatment of PD. Many of the oral therapies studied improved patient outcomes, but the data are insufficient. Similarly, there is no approved topical therapy by guidelines. The best options are intralesional injections of collagenase Clostridium histolyticum (CCh) and interferon-α2b. Shock wave therapy is not recommended for treatment of curvature, but has been shown to improve pain. Traction therapy may have a role in improving PD curve and penile length. CONCLUSION:PD remains a challenge for urologists. Evidence suggests that, for oral therapy, a combination of drugs produces better results. Shock wave therapy is still unproven. Intralesional therapy delivers the best evidence for improvement in the active phase. CCh is the only FDA-approved treatment option available. Penile traction therapy may improve patient outcomes. Brimley SC, Yafi FA, Greenberg J, et al. Review of Management Options for Active-Phase Peyronie's Disease. Sex Med Rev 2019;7:329-337.
Authors: Andrea Cocci; Fabrizio Di Maida; Giorgio Ivan Russo; Paolo Capogrosso; Lotti Francesco; Michele Rizzo; Marina Di Mauro; Andrea Salonia; Gianmartin Cito; Marco Falcone; Andrea Romano; Gaia Polloni; Juan Ignacio Martinez-Salamanca; Esaù Fernández-Pascual; Andrea Minervini; Nicola Mondaini Journal: Clin Drug Investig Date: 2020-06 Impact factor: 2.859
Authors: Fabrizio Di Maida; Gianmartin Cito; Luca Lambertini; Francesca Valastro; Girolamo Morelli; Andrea Mari; Marco Carini; Andrea Minervini; Andrea Cocci Journal: World J Mens Health Date: 2020-07-08 Impact factor: 5.400
Authors: Andrea Cocci; Fabrizio Di Maida; Gianmartin Cito; Pierangelo Verrienti; Nicola Laruccia; Riccardo Campi; Andrea Mari; Marina Di Mauro; Marco Falcone; Giovanni E Cacciamani; Giulio Garaffa; Andrea Minervini; Giorgio Ivan Russo Journal: World J Mens Health Date: 2020-01-20 Impact factor: 5.400
Authors: Vincenzo Maria Altieri; Francesco Greco; Rocca Carmela Lisanti; Barbara Altieri; Francesco Esperto; Luca Cindolo; Roberto Castellucci; Pier Andrea Della Camera; Giuseppe Massimo Sangiorgi; Vittore Verratti Journal: Transl Androl Urol Date: 2021-07
Authors: Odinachi I Moghalu; Rupam Das; Joshua Horns; Alexander Campbell; James M Hotaling; Alexander W Pastuszak Journal: Int J Impot Res Date: 2021-04-07 Impact factor: 2.408
Authors: Ming-Yeah Y Hu; John T Sigalos; Dyvon T Walker; Michelle K Li; Dar A Yoffe; Neilufar Modiri; Thomas W Gaither; Alvaro J Santamaria; Keith V Regets; Sriram V Eleswarapu; Jesse N Mills Journal: Transl Androl Urol Date: 2022-08